DCP - Support to NSRG
DCP - 对 NSRG 的支持
基本信息
- 批准号:10329763
- 负责人:
- 金额:$ 25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-31 至 2021-08-30
- 项目状态:已结题
- 来源:
- 关键词:AreaClinical Trials DesignContractorContractsDevelopmentDevelopment PlansKnowledgeLaboratoriesMonitorNursing ResearchPerformancePhaseProceduresProtocols documentationQuality ControlRegulatory AffairsSiteSpecialistSpecimenTherapeuticVaccinesclinical developmentexperiencehuman biological materialoperationpre-clinicalprocess optimizationproduct developmentprogramspublic-private partnershipquality assuranceresearch clinical testingskillstherapeutic development
项目摘要
The Contractor shall conduct program analysis activities upon request and provide on-site staff to assist in creation of product development plans for vaccines and therapeutics. The Contractor shall provide information and knowledge in areas including but not limited to: product (vaccine or therapeutic) development analysis; creation of target product profiles; preclinical strategy; manufacturing capacity analysis; regulatory strategy; clinical development strategy with transition plan to advanced phase clinical testing; candidate down-selection strategy; and market analysis of public-private partnerships. The Contractor shall identify deficiencies in these areas, and independently close those deficiencies using their skills and abilities and those of subcontractors.
承包商应根据要求开展项目分析活动,并提供现场工作人员协助制定疫苗和治疗药物的产品开发计划。承包商应提供以下领域的信息和知识,包括但不限于:产品(疫苗或治疗药物)开发分析;目标产品概况创建;临床前策略;生产能力分析;监管策略;临床开发策略,以及向高级阶段临床试验的过渡计划;候选人下选策略;以及公私合作伙伴关系的市场分析。承包商应确定这些方面的缺陷,并利用其自身和分包商的技能和能力独立弥补这些缺陷。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LEONARD FREEDMAN其他文献
LEONARD FREEDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LEONARD FREEDMAN', 18)}}的其他基金
DCP - Pilot - Biomarker Reference Laboratory
DCP - 试点 - 生物标志物参考实验室
- 批准号:
10282237 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别:
DCP - Clinical Trials Regulatory & Monitoring Support for US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network
DCP - 临床试验监管
- 批准号:
10282236 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别:
DCP - Biopharmaceutical Development Program (BDP) Support
DCP - 生物制药开发计划 (BDP) 支持
- 批准号:
10282235 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别:
DCEG- Repository Services for epidemiology studies
DCEG-流行病学研究存储库服务
- 批准号:
10273214 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别:
DCEG- Molecular Assays for epidemiology studies
DCEG-流行病学研究的分子测定
- 批准号:
10273216 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别:
VENTANA PD-L1 (SP142), a complimentary diagnostic immunohistochemistry (IHC) assay to ascertain tumor PD-L1 status for patients with metastatic urothelial cancer considering treatment with atezolizuma
VENTANA PD-L1 (SP142),一种免费的诊断性免疫组织化学 (IHC) 检测,用于确定考虑使用 atezolizuma 治疗的转移性尿路上皮癌患者的肿瘤 PD-L1 状态
- 批准号:
10273221 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别:
THE COVID 19 SERVICES CATALYZE TRANSLATIONAL RESEARCH FINDINGS INTO PUBLIC HEALTH CHANGES TO ADDRESS THE NOVEL CORONAVIRUS PANDEMIC THROUGH IMPLEMENTA
COVID 19 服务促进公共卫生变革的转化研究成果,通过实施应对新型冠状病毒大流行
- 批准号:
10500611 - 财政年份:2020
- 资助金额:
$ 25万 - 项目类别: